Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride
https://doi.org/10.14341/2072-0351-6017
Abstract
Type 2 diabetes is believed to develop as a result of lowered insulin secretion and insulin resistance leading to hyperglycemia. Sulfonylureas stimulateinsulin secretion and thereby decrease blood glucose level which accounts for their wide application in the treatment of diabetes. However, manyagents of this class produce side effects (increased body mass, hypoglycemia, resistance to therapy, etc.) attributable to excess stimulation of insulinsecretion. Glimepiride is as efficient as traditionally used sulfonylureas but causes a smaller rise in insulin secretion. Sulfonylurea receptors showlower affinity for glimepiride than for glibenclamide. Formation and dissociation of glimepiride-receptor complexes occur faster than those of glibenclamide-receptor complexes. In addition, therapeutic effect of glimepiride was shown to be associated with improved insulin sensitivity. It is concludedthat glimepiride is an efficacious agent for the treatment of type 2 diabetes.
About the Authors
Tatiana Ivanovna Romantsova
I.M. Sechenov Moscow Medical Academy
Nadezhda Viktorovna Maksimova
I.M. Sechenov Moscow Medical Academy
References
1. Дедов И.И., Шестакова М.В. Сахарный диабет. Руководство для врачей. - М.: Универсум Паблишинг, 2003. - 455 с.
2. Дедов И.И., Демидова И.Ю. Бигуаниды в современной практике лечения сахарного диабета 2 типа. Пособие для врачей. - М.: 1999. - 42 с.
3. Ward W.K., Beard J.C., Halter J.B. et al. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus // Diabetes Care. - 1984. - 7. - P. 491-502.
4. Nathan D.M., Buse J.B., Davidson M.B. et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A consensus Algorithm for the Initiation and Adjustment of therapy // Diabetes Care. - 2009. - Vol. 32, 1. - P. 193-203.
5. Александров А.А., Галстян Г.Р., Григорян Г.Р., Кураева Т.Л., Липатов Д.В., Майоров А.Ю., Миленькая Т.М., Петеркова В.А., Токмакова А.Ю., Смирнова О.М., Суркова Е.В., Сухарева О.Ю., Чугу- нова Л.А., Шамхалова М.Ш. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой. - М., 2009. - 104 с.
6. Holstein A., Plaschke A., Egberts E.H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide // Diabetes. Metab. Res. Rev. - 2001. - 17(6). - Р. 467-473.
7. Knowler W.C., Barrlett-Connor E., Fowler S.E. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin // N. Engl. J. Med. - 2002. - 346. - Р. 393-403.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - Sep. 12; 352(9131). - P. 854-865.
9. Мкртумян А.М. О лечении сахарного диабета 2 типа глимепири дом // Сахарный диабет. - 2000. - №4. - C. 20-24.
10. Korytkowski M., Thomas A., Reid L. et al. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes // Diabetes Care. - 2002. - 25. - Р. 1607-1611.
11. Muller G., Hartz D., Punter J. et al. Differential interaction of glimepiride and glibenclamide with the -cell sulfonylurea receptor. II Photoaffinity labeling of a 65 kDa protein by [3H] glimepiride // Biochim Biophys Acta. - 1994. - 1191. - P. 267-277.
12. Jacobs D.B., Hayes G.R., Lockwood D.H. Effect of chlorpropamide on glucose transport in adipocytes in the absence of changes in insulin binding and receptor-associated tyrosine kinase activity // Metabolism. - 1987. - 36. - Р. 548-554.
13. Инструкция по медицинскому применению препарата АмарилR. Регистрационный номер П №015530/01 от 12.04.2004 г.
14. Шустов С.Б., Ромашевский Б.В., Лысенко А.Г. Влияние АмарилаR на углеводный, липидный обмен и гемодинамику у больных сахарным диабетом 2 типа // Сахарный диабет. - 2001. - №4. - С. 42-45.
15. Александров А.А. Сахароснижающая терапия и сердце: бремя до- казательств // Consilium Medicum. - 2002. - Т. 4, №10. - C. 551- 554.
16. Klepzig H., Kober G., Matter C., at al. Sulfonylureas and ischemic preconditioning; a double - blind, placebo - controlled evaluation of glimepiride and glibenclamide // Eur. Heart. J. - 1999. - 20. - P. 439.
17. Lehr K.H., Damm P. Simultaneous determination of the sulfonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivati zation // J. Chromatogr. - 1990. - 497. - P. 526.
18. Kabadi U. M. Cost-effective management of hyperglycemia in patient with type 2 diabetes using oral agents //Managed Care. - 2004. - 6. - Р. 48-59.
19. Garber A.J., Duncan T.G., Goodman A.M. et al. Efficacy of Metformin in Type II Diabetes: Results of a Double-blind, Placebo-controlled, Dose-response Trial // Am. J. Med. - 1997. - Vol. 103. - P. 491- 497.
20. Charpentier G., Fleury F., Kabir M. et. al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients // Diabet. Med. - 2001. - 18(10). - Р. 828-834.
21. Riddle M. Combining sulfonylureas and other oral agents // The American Journal of Medicine. - 2000. - Volume 108, Issue 4. - P. 15-22.
22. Chelim C., Jamie C.B., Kenneth A.L., Michael T.J. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among texas medicaid recipients // Clinical Therapeutics. - 2008. - 30, Issue 10. - Р. 1893- 1907.
Review
For citations:
Romantsova T.I., Maksimova N.V. Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride. Diabetes mellitus. 2010;13(1):50-54. (In Russ.) https://doi.org/10.14341/2072-0351-6017
Views:
2607
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
